Mycenax ADC Integrated Services

Antibody-drug conjugates (ADCs) represent a rapidly evolving class of targeted cancer therapies. These constructs combine the specificity of monoclonal antibodies with the potency of cytotoxic small molecules. A cleavable or non-cleavable linker connects these moieties, allowing the ADC to selectively deliver the cytotoxic payload to cancer cells. The past few years have witnessed significant progress in the development of ADCs, with over 14 approved drugs and numerous investigational agents in clinical trials. Notably, ADCs demonstrate therapeutic potential beyond oncology, showing promise in autoimmune disorders, infectious diseases, and inflammatory conditions.

Mycenax, capitalizing on its established protein drug manufacturing platform, has expanded its services to encompass the ADC field. Through strategic partnerships, Mycenax offers a comprehensive, one-stop solution for ADC development. This service encompasses the entire process, from antibody modification and small molecule synthesis to conjugation, analysis, characterization, and ultimately, GMP production under PIC/S guidelines. Learn how our integrated approach effectively assists clients in navigating the complexities of ADC development.